Top Healthcare Gainers - Zogenix (ZGNX), MAKO Surgical (MAKO), Optimer Pharmaceuticals (OPTR)

New York, NY -- (SBWIRE) -- 02/28/2013 -- StockRunway.com issues special report on Top Healthcare Gainers – Zogenix, Inc. (NASDAQ:ZGNX), MAKO Surgical Corp. (NASDAQ:MAKO), Optimer Pharmaceuticals, Inc.(NASDAQ:OPTR).

Zogenix, Inc.(NASDAQ:ZGNX) gained +40.50% with the closing price of $1.70on higher investor hope of U.S. regulatory approval.The San Diego-based company stated recently that the Food and Drug Administration said it will not be able to follow a March 1 deadline to decide whether to approve the painkiller, called Zohydro, because the regulatory authority needs more time to review data. Analysts at Leerink Swann & Co. and Wells Fargo Securities LLC suggested that the delay means the drug likely will be approved.

What was the Moving Force behind ZGNX On Bullish Run? Read This Research Report on ZGNX

The overall volume in the last trading session was 11.35 million shares. Its fifty two week range was $1.11-$3.30. The total market capitalization remained $171.13million.The stock is ahead its 52 week low with 53.15% and its last month price volatility remained 8.57% with a target price of $3.00. In its share capital, the company has 100.67 million outstanding shares while 99.54 million shares have been floated in market.

It has insider ownership of 0.51% with institutional ownership remained 73.62%. Earnings per share this year grew 0.51%.

MAKO Surgical Corp. (NASDAQ:MAKO) surged +9.91% after releasing its fourth-quarter financial results.

The Davie-based manufacturer of a hip and knee replacement surgical robot posteda fourth quarter net loss of $0.13 per share, lower versus the loss of $0.14 per share a year ago. The mean forecast was for a loss of $0.11.

The stock closed at $12.09 in the last trading session with the overall traded volume of 4.18 million shares, more versus the average volume of 1.20 million shares. Its 52 weeks high price was $45.15 and suffered lowest price of $10.35 in the same period.

For How Long MAKO will Fight for Profitability? Read This Trend Analysis report

MAKO has current ratio of 4.21. It has market cap of $555.41million while its total outstanding shares are 45.94million. The stock beta value stands at 0.49 times.

Optimer Pharmaceuticals, Inc.(NASDAQ:OPTR) jumped +13.15% with the closing price of $12.13 after naming its Chairman, Henry McKinnell, as its chief executive to replace Pedro Lichtingerand explore strategic options.The company also named Mark Auerbach, who served as an Optimer Director since June 2005, as Lead Independent Director.The overall volume in the last trading session was 4.18 million shares. Its fifty two week range was $8.64-$16.49. The total market capitalization remained $578.49million.

For How Long OPTR’s Gloss will Attract Investors? Find out via this report

OPTR is ahead its 52 week low with 40.39% and its last month price volatility remained 4.41%. Its beta coefficient was 0.43 with a target price of $17.05. In its share capital, the company has 47.69million outstanding shares while 46.08million shares have been floated in market. It has insider ownership of 0.68% with its institutional ownership remained 87.87%. EPS this year advanced 113.48%.

About StockRunway.com
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.

Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!

Disclaimer
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.